Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Meda has signed an exclusive licensing agreement with the Swedish development company Medivir for Xerese. Meda’s exclusive rights cover the US, Canada and Mexico.
Subscribe to our email newsletter
Xerese (formerly Lipsovir, ME-609), used for topical treatment of herpes labialis (cold sores), contains a combination of the antiviral substance acyclovir and hydrocortisone.
Xerese is the first topical treatment indicated to both reduce the likelihood of cold sores as well as shorten the healing time of existing cold sore lesions. Xerese was approved by the FDA as a prescription drug during 2009.
In consideration for exclusive rights to Xerese, Meda is expected to pay Medivir a total of $5m in up-front and pre-launch milestones. Additionally, Meda will also pay Medivir double-digit royalties on sales.
Anders Lonner CEO at Meda, said: “Xerese is a very interesting addition to our product portfolio in the US. It’s already registered and has a unique and differentiating claim. When commercial stock is in place we will launch the product. We look forward to the collaboration with Medivir and that we together can develop new indications for Xerese.”